Comparison of Dapagliflozin and Empagliflozin in Patients with Heart Failure: Systematic Review

Abstract

Background: This systematic review examines the efficacy and safety of dapagliflozin and empagliflozin in managing heart failure across various patient populations. Methods: Recent studies were analyzed to assess the impact of both agents on heart failure events, cardiac function, and quality of life. Results: Findings indicate that both dapagliflozin and empagliflozin significantly reduce heart failure events and improve overall patient well-being. The DELIVER trial highlights dapagliflozin’s effectiveness in preventing adverse cardiovascular outcomes, while empagliflozin demonstrates positive effects on cardiac structure. Conclusions: Despite these promising results, several limitations exist, including variability in study designs, sample sizes, and follow-up durations, which may affect the generalizability of the findings. Potential biases and a lack of mechanistic understanding necessitate further research to optimize treatment protocols and enhance patient outcomes in heart failure management.